'his soul jealously guarded its last strength for the most essential tasks while his body was almost consumed'. This last period of Bartók's creativity is characterized by radical change. Bartók seems to have withdrawn from his earlier more avant-garde musical style in his last compositions, possibly in view of his illness, the devastation of Europe during World War II, or both. This music seems to retrospectively summarize his musical past by incorporating folkloristic Hungarian elements, rhythms of great vitality, a harmonic organization of sound and beautiful lyrical aestheticism, such as found in his Concerto for Orchestra, while lacking any kind of extremism. May the knowledge of having an incurable disease and the physical suffering Bartók experienced have led to a reversal of his composing style? Bartók's third piano concerto, written on his sick bed, differs significantly from his first two piano concerti. Specifically, the second movement is breathtakingly beautiful. The concerto is traditional, harmonic, pastoral, naive-idyllic, romantic, even joyful and boasts delicate sensitive rhythms, while disharmonies are discreet and aggressivity is lacking. The musical richness of the viola concerto, in fact, is said to even exceed that of the third piano concerto. Similarly, the solo violin sonata, inspired by Bach's solo sonatas, is marked by a pastoral and almost archaic style and a solemn thoughtfulness.
We will never know what went on in Bartók's mind-or even in the minds of our patients with a terminal illness-while he was composing his painfully aesthetical third piano concerto or how illness may influence artistic creativity, but Bartók did say: 'The trouble is that I go away with a full trunk (that is, full of creative spirit)'. Those were his last words.
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The author declares no conflict of interest. fluorescence in situ hybridization, including these immunoglobulin heavy chain translocations, can be predicted with high accuracy by spiked gene expression levels with a technique known as virtual karyotyping. 3, 4 In the present study, we investigate whether SNPs previously associated with overall risk of MM 5-7 and t(11;14) 1 are associated with any disease-specific subset. We also performed genome-wide scans of associations between common genetic variants to molecular subgroups. Genotypes at 777 681 SNPs in a discovery set of 972 newly diagnosed MM patients of European ancestry and 1064 cancerfree controls, plus a replication set of 252 more recent European ancestry patients genotyped at selected SNPs, form the basis of this analysis. 7 The study was conducted under the auspices of the Institutional Review Board at the University of Arkansas for Medical Sciences. Gene expression profiling from CD138-selected plasma cells from these patients within 3 months before treatment 8 was available for 650 patients in the discovery set and for all 252 patients in the replication set. Patients included in specific MM subgroups served as cases and were compared with 1064 non-cancer controls. The results of this analysis showed that one SNP was significantly associated with Cyclin D1 spiked expression (CCND1-hi) and one SNP was significantly associated with the proliferation (PR) subgroup (Table S1 ).
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The SNP rs603965, located in the CCND1 gene at 11q13.3, was significantly associated with CCND1-hi in the discovery set (118 patients, odds ration (OR) = 1.66, P = 3.6 × 10 -4 , Table 1 ), and this association was confirmed in the replication set (64 patients, OR = 1.90, P = 0.001). A significant allele dosage effect was seen on gene expression levels of CCND1 ( Figure S1 ). Interestingly, overall survival among the combined cohorts of CCND1-hi patients was poorer among non-carriers of the G-allele than either heterozygous or homozygous carriers (P = 0.008, Figure 1 ).
The SNP rs73486634 at 9q22.33, located between and upstream of the forkhead box E1 (FOXE1) and xeroderma pigmentosum complementation group A (XPA) genes, was associated with the PR subgroup in the MM discovery set (78 patients, OR = 5.06, P = 6.0 × 10 -9 , Table 1 ). This association was confirmed in the replication set (45 patients, OR = 3.16, P = 0.006). A trend was observed between variant carriers of rs73486634 and poorer overall survival ( Figure 1 , P = 0.115). The PR subgroup is characterized by a significantly higher gene expression PR index and overexpression of genes involved in regulation of cell cycle as compared with the other molecular subgroups. 2 The subgroup has poor clinical outcome and close to 70% of the cases in this subgroup have cytogenetic abnormalities. 2 The FOXE1 gene, also named thyroid transcription factor 2, is an intron less gene that encodes an evolutionary conserved transcription factor highly overexpressed in thyroid follicular cells. Changes in the gene may be involved in carcinogenesis. 9 The protein encoded by the DNA excision repair gene XPA is crucial for global genomic nucleotide excision repair, which corrects lesion in the entire genome including the non-transcribed strands of active genes and is closely coupled to DNA damage checkpoint. 10 Polymorphisms in the XPA gene and susceptibility to several cancers have been described by a targeted SNP approach. The association we find could represent a cancer etiological factor or a tendency to develop a proliferative behavior to be associated with disease progression.
In addition to testing SNPs known to be associated with overall risk of MM, we also performed genome-wide scans of GEP-defined subgroups using the genotype data previously described. 7 First, an MM-case-only analysis was performed on each GEP-defined subgroup, with MM patients not belonging to the subgroup serving as controls (Supplementary Table 2 ). By using MM patients as controls, we ensured that genetic associations were specific to a subgroup and were not simply a recapitulation of associations to overall MM risk. In Supplementary Figure 2 , we also show the results of a confirmatory analysis using cancer-free individuals, instead of non-subgroup MM patients, as controls.
These genomic scans identified one region containing multiple SNPs significantly associated with risk of the cMAF-hi subgroup. The most significant SNP, rs4666188, was associated with risk of belonging to the cMAF-hi subgroup when compared with cancerfree controls (OR = 4.1; P = 1.2E-7; Supplementary Table 2 ). The SNP is located in an intron in ALK (anaplastic lymphoma receptor tyrosine kinase) at 2q23.2 and is in linkage disequilibrium with the SNP rs35093491, which results in an amino-acid change at residue 476. An allele dose effect of rs4666188 in the ALK gene was found for gene expression levels of cMAF and ALK ( Supplementary Figure 3 ). Risk allele carriers had higher gene expression levels of cMAF in contrast to the gene expression level of ALK where the levels were highest among homozygous wild-type G-allele carriers. The transmembrane tyrosine kinase encoded by the ALK gene is involved in the development of the brain and nervous system. Rearrangements at locus 2p21.2 are found in many cancers but no translocations in the ALK break point at 2p23 were found by metaphase cytogenetic analysis among patient in the cMAF subgroup. Elevated expression levels of cMAF are found in MM with t(14;16) and t(4;14) and inhibition of MEK has been shown to deplete Letters to the Editor MAF expression levels both in patients with MMSET overexpression and in those with t(14;16). 11 The SNP rs16897930 (at 6q27) was associated to risk of the MMSET-hi subtype (OR = 2.5; P = 1.2E-05). The SNP rs16897930 is located in an intron of PDE10A (phosphodiesterase 10A) and encodes a protein that is important for signal transduction by regulating the intracellular concentration of cyclic nucleotides. The phosphodiesterase encoded by PDE10A gene has recently been shown to be a target of curcumin, a drug that has shown apoptotic effect in myeloma cell lines including those with t(4;14) and t(14;16). 12, 13 Unfortunately, the allele frequency of the significant SNPs, rs4666188 and rs16897930, was too low for validation of the results in the small number of patients in the replication set.
In conclusion, we confirm the association of rs603965 to t(11,14) and our results indicate that this SNP may have prognostic importance. We also identify a novel association between the SNP rs73486634 and the PR molecular subgroup as an inherited contributor to the development of proliferative disease. Mutations in the metabolic enzymes isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2) occur in~15-20% of patients with acute myeloid leukemia (AML). 1 A consequence is the aberrant accumulation of the (D)-enantiomer of 2-hydroxyglutarate (D-2-HG), a putative oncometabolite that competitively inhibits α-ketoglutarate-dependent epigenetic regulators such as TET2 and Jumonji domain histone demethylases. 2 The presence of elevated 2-HG (either total or more specifically the D-enantiomer) in plasma or serum accurately identifies AML patients with IDH1 or IDH2 mutations, and 2-HG levels mirror disease burden. [3] [4] [5] [6] However, it is not yet known whether 2-HG measurement represents the optimal approach to monitoring IDH mutant (IDH mut ) allele burden during and after therapy, or whether alternative strategies such as allele-specific digital PCR may be equivalent or superior. Indeed, an evaluation of digital PCR in IDHmutated AML has not yet been reported. Accurate assessment of mutant allele burden is essential to guide therapy and to predict prognosis, the more so given recent promising results from early phase trials of selective IDH mut inhibitors. 7 To address this question, we have developed an allele-specific digital PCR method for recurring IDH1 and IDH2 mutations in AML, and made a direct comparison with 2-HG D:L enantiomeric ratios in concomitantly collected plasma samples. The 2-HG D:L ratio has recently been reported to be a more specific test for detection of patients with IDH mutations than total 2-HG alone. 6 Digital PCR enables the quantitative identification of single-nucleotide variants (SNVs) against a wild-type DNA background. It relies on the random distribution of DNA molecules in multiple partitions of starting sample. Provided a sufficient number of partitions, and sufficient dilution to ensure that not every partition contains a target, Poisson statistics can estimate the number of SNV targets per partition in a binary manner, independent of exponential kinetics or reliance on standard curves. It has been made clinically practicable by the advent of nanofluidic and droplet-based partitioning platforms and has been applied to quantitate rare mutations in several cancers, including NPM1 mut AML 8 and ABL kinase domain mutations in chronic myeloid leukemia. 9 It is more sensitive than Sanger sequencing (which has a mutant allele frequency (MAF) detection threshold of~5-20%), and less burdensome and substantially cheaper than next-generation sequencing.
We assessed the D-2-HG:L-2-HG ratio in plasma samples collected from 192 consecutive patients presenting between February 2010 and December 2014 to The Christie NHS Foundation Trust in Manchester, UK, with newly diagnosed refractory cytopenia with multilineage dysplasia (RCMD; n = 21), refractory anemia with excess blasts (RAEB; n = 28) or AML (n = 116); or with relapsed AML (n = 27; Supplementary Figure S1 and Supplementary Table S1 ). In each case platelet-poor plasma and mononuclear cells from blood and/or bone marrow (BM) were cryopreserved at presentation and at frequent intervals thereafter. IDH mut cases were identified by Sanger sequencing of genomic DNA from presentation samples, with the exception of two cases where only blood mononuclear cells containing a low frequency of blasts were available for analysis. 5 In these cases digital PCR provided the diagnosis where Sanger sequencing was unable to. Presentation and follow-up plasma samples were blindly screened for 2-HG stereoisomers by ultra-performance liquid chromatography with tandem mass spectrometry (Supplementary Figure S2) . 10 For digital PCR, we first designed and validated Taqman SNP genotyping quantitative PCR assays for the six most common IDH mutations (IDH1 R132C/G/H/S ; IDH2 R140Q/R172K ), comprising pooled common primers with FAM-and VIC-dye-labeled probes specific for each mutant or wild-type sequence, respectively ( Supplementary Figures S3-S5 ). Allelic discrimination quantitative PCR clearly and correctly distinguished IDH mut from IDH wt patients in all replicates from all cases for each assay (Supplementary Figure S5 ). We then used these validated quantitative PCR assays in a digital PCR protocol using a nanofluidic platform and 37 K integrated fluidic circuit chips (Fluidigm, San Francisco, CA, USA; Supplementary Information). Digital PCR assays provided excellent reproducibility between replicates throughout the MAF range (R 2 = 0.994; Supplementary Figures S6A and B) and were validated as quantitative to ⩽ 0.1% in spiking experiments (Supplementary Figure S7 ).
As expected, 6 the mean (± s.d.) plasma D-2-HG:L-2-HG ratio was significantly higher in IDH mut versus IDH wt patients (41.8 ±28.2; Figure 1a ), with a ratio ⩾ 1.93 identifying the 36 IDH mut cases at presentation with 100% sensitivity and 95% specificity ( Figure 1b ) and a ratio ⩾ 4.26 identifying IDH mut cases with a unique performance of 100% sensitivity and 100% specificity (Figure 1b) . The mean ± s.d. for plasma D-2-HG:L-2-HG ratio for IDH wt patients was 1.0 ± 0.58 (Figure 1a ). IDH mut frequencies for RCMD (2/21; 9.5%), RAEB (4/28; 14.3%) and AML (30/143; 21.0%) were also as expected. 11 For the comparison of enantiomeric ratio versus digital PCR, in addition to presentation samples from 36 IDH mut patients, there were follow-up serial plasma and cell samples available for 30 of these cases (median 7 samples per patient; range 2-20; median follow-up 27.6 months). Together, there were a total of 205 matched plasma and cellular genomic DNA pairs for analysis, spanning a wide range of mutant allele Accepted article preview online 19 June 2015; advance online publication, 14 July 2015
